Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle. Recent findings Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent...
-
September 30, 2024 (v1)Journal articleUploaded on: October 26, 2024
-
May 31, 2024 (v1)Journal article
BACKGROUND: This study aimed to compare the humoral responses to mRNA COVID-19 vaccination in PWH and HIV-negative individuals. METHODS: We included PWH with an undetectable viral load under ART and HIV-negative participants from the French nationwide ANRS COV-POPART cohort who had received two doses of vaccine as a primary vaccination. We...
Uploaded on: July 2, 2024